Navigation Links
Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
Date:10/8/2009

SAN DIEGO, Oct. 8 /PRNewswire/ -- Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that Randy White, Ph.D. chief executive officer, will present initial data supporting direct detection of DNA targets in human clinical samples during company presentations at the following conferences:

  • AdvaMed 2009 on Tuesday, October 13, 2009 at 10:00 a.m. Eastern Time at the Walter E. Washington Convention Center in Washington, D.C.
  • BIOCOM's 4th Annual Investor Conference on Monday, October 26, 2009 at 10:00 a.m. Pacific Time at the Hyatt Regency La Jolla in San Diego, California.

"The hallmark of Adnavance's direct detection technology is its simplicity; it doesn't require PCR, light detection, or sample pre-treatment. We are highly encouraged by our initial data supporting the utility of our technology and its potential for use in medium complexity laboratories," said Dr. White. "Our mission is to de-centralize molecular diagnostics."

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of its proprietary technology that allows direct-detection of DNA targets in human clinical samples. The Company is located in San Diego, CA. The Company's patented technology is based on the change in surface charge on a gold electrode when DNA targets hybridize with capture probes anchored to the electrode surface. The Company uses a microarray of electrodes in an electrochemical cell to detect the target DNA and the inherent ultra-sensitivity of electrochemical measurements obviates the need for target amplification used in current molecular-based tests. In addition, the electrochemical measurement simplifies the medical device and eliminates sample pre-treatment steps required for PCR-based tests. Adnavance scientists were the first to discover the surface charge phenomenon, and the Company believes its technology platform will open new molecular testing markets. For additional information please see the Company website at www.adnavance.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate," and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.

    Media Contact:
    Kim Richards
    Porter Novelli Life Sciences
    619-849-5377
    krichards@pnlifesciences.com

SOURCE Adnavance Technologies Inc.


'/>"/>
SOURCE Adnavance Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Noninvasive Medical Technologies Awarded ISO 13485 Quality Certification
2. ReBuilder Medical Technologies, Inc. Hiring! Increases Staff by 40%
3. Wound Management Technologies Acquires Resorbable Orthopedics
4. Blue Belt Technologies, Inc. Closes Series A Financing
5. ReBuilder Medical Technologies, Inc. Reports LOI With National DME Distributor
6. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
7. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
8. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
9. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
10. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
11. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):